Overview
- Editors:
-
-
Elie Azoulay
-
Service de Réanimation Médicale, Hôpital Saint Louis, Paris, France
Detailed, up-to-date information is provided on all relevant aspects of pulmonary involvement in patients with hematological malignancies
Leading experts discuss epidemiology, diagnostic strategy, lung infections, non-infectious pulmonary involvement, and treatment, including decision making in patients with acute respiratory failure
Invaluable "pearls" relating to each condition are presented
Includes supplementary material: sn.pub/extras
Access this book
Other ways to access
Table of contents (73 chapters)
-
Noninfectious Pulmonary Involvement In Patients With HM
-
- Rachel S. Bercovitz, J. Bradley Ball, Marguerite R. Kelher, Christopher C. Silliman
Pages 461-475
-
- Mokart Djamel, Textoris Julien, Ettori Florence, Bruno Chetaille, Blache Jean-Louis
Pages 477-490
-
- Matthew C. Bunte, Linda J. Burns
Pages 491-498
-
- Miguel Gallego Díaz, Jordi Rello Condomines
Pages 499-507
-
-
- Marie Wislez, Raphael Borie, Catherine Thieblemont, Marie-France Carette, Martine Antoine, Jacques Cadranel
Pages 521-531
-
- Élie Azoulay, Eric Ezingeard, Choupi-Salomon Berckowski, Michael Darmon
Pages 533-536
-
- Huda Salman, Kenneth R. Cooke, Hillard M. Lazarus
Pages 537-550
-
Treatment and Difficult Decisions in Patients with HM and ARF
-
Front Matter
Pages 551-551
-
Treatment And Difficult Decisions In Patients With HM And ARF
-
- Matthieu Legrand, Adeline Max, Bertrand Gachot
Pages 553-567
-
- Raoul Herbrecht, Yasmine Nivoix
Pages 569-588
-
-
- Márcio Soares, Jorge I. F. Salluh, Pieter O. Depuydt
Pages 597-606
-
-
- Massimo Antonelli, Giuseppe Bello, Riccardo Maviglia
Pages 617-622
-
- Stefano Nava, Sebastiano Mercadante
Pages 623-629
-
- Anne-Pascale Meert, Thierry Berghmans, Jean-Paul Sculier
Pages 631-635
-
- Michael Darmon, Laurent Camous, Camille Devanlay, Emmanuel Canet, Benoit Schlemmer, Fabrice Zeni
Pages 637-650
-
- David Grimaldi, Frédéric Pène
Pages 651-663
-
- Kathleen N. S. Cathcart, Jeffrey S. Groeger
Pages 665-670
About this book
The number of patients treated for hematological malignancies is increasing steadily. To maximize cure rates, aggressive treatments have been introduced, including high-dose chemotherapy, stem cell transplantation, and targeted therapies. As a result, overall and disease-free survival rates have improved substantially, but at the price of life-threatening toxic and infectious complications that chiefly target the lung. This book provides clinicians caring for patients with hematological malignancies with detailed, up-to-date information on all relevant aspects of pulmonary involvement. Individual sections are devoted to epidemiology, diagnostic strategy, lung infections, non-infectious pulmonary involvement, and treatment, including decision making in patients with acute respiratory failure. Each of these sections contains a number of chapters, all written by leading international experts. In addition, the reader’s attention is drawn to important "pearls" relating to each condition.
Reviews
From the reviews:
“This is a detailed, multiauthored review of infectious, inflammatory, and thromboembolic complications in patients with a variety of hematological cancers. … Practitioners with an interest in hematological malignancy and intensivists providing critical care resources for management of these patients are an appropriate audience for this work coming from an international panel of authors, the majority of whom are from France. … This unique book effectively reviews the current therapy, incidence, and outcomes for this complex patient group.” (David J. Dries, Doody’s Review Service, December, 2011)
Editors and Affiliations
-
Service de Réanimation Médicale, Hôpital Saint Louis, Paris, France
Elie Azoulay
About the editor
Dr Élie Azoulay is the Assistant Director of the Medical ICU at the Saint-Louis Teaching Hospital, Paris, France. He is a professor of medicine at the Denis Diderot Paris 7 University. From his background as a pulmonologist, Dr Azoulay developed a strong research focus on acute respiratory failure in immunocompromized patients. His PhD work was on respiratory physiology in an experimental model of cancer chemotherapy-related pulmonary toxicity. He has several published clinical research studies on acute respiratory failure in hematology and oncology patients. Also, Dr Azoulay leads a collaborative multicenter group that has performed observational studies, large cohort studies, and randomized controlled trials in cancer patients with ARF. His second major field of interest in clinical research is communication with family members of ICU patients. He constituted a research group in 1997 (the French Famirea Study Group) to evaluate the ability of critical care clinicians to provide effective information to ICU patients and families. Several of his published studies investigated the burden of critical illness in relatives and in ICU clinicians. The group’s major aim is to identify targets for improvement and to test potential interventions in international RCTs in order to advance ICU practices in the field of information and communication. In addition to clinical and research activities, Dr Azoulay teaches pulmonary medicine, critical care medicine, and ethics at the Paris Medical School. He is also associate editor of Intensive Care Medicine, in the editorial board of the American Journal of respiratory and Critical Care medicine, and the chairman of the ethics section of the ESICM. Dr Azoulay is a member of the European board of Pfizer and Gilead.